Pfizer Requests US Emergency Authorisation For Covid Booster For Adults

Drugmakers Pfizer and BioNTech announced Tuesday they have formally submitted a request asking US officials for emergency authorization of their Covid-19 booster vaccine for people aged 18 and older.

The move follows research published by the companies in late October indicating a third shot is 95.6 percent effective against symptomatic infection, based on clinical trials carried out on 10,000 people.

The companies asked the US Food and Drug Administration to add the new population segment, amending emergency use authorization already granted in September for a third dose for everyone aged 65 and up, as well as people at high risk of developing severe Covid-19.